Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study

Fig. 5

Liver a, b and renal function c test results through the run-in (weeks − 4 to 0) and treatment (weeks 0 to 52) periods. Week − 4 values were measured prior to methotrexate exposure. Week 0 (day 1) values were measured prior to pegloticase exposure. The number of patients with liver function tests above the upper limits of normal and estimated glomerular filtration rate < 60 mL/min/1.73 m.2 are also shown d. Error bars represent the standard deviation. ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate (calculated from serum creatinine measurements using the MDRD equation)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us